Liminatus Pharma, Inc. Class A Common Stock
LIMNStock
$0.15−98.36%52W
Market Cap$5.24M
P/E—
Div yield—
Beta0.73
Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-93.11%
Price vs S&P 500 (4W)-13.42%
VGM Score5.74
Market Capitalization$5.24M
Industry Peers — Biological Products(180)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
LIMNLiminatus Pharma, Inc. Class A Common Stock | — | — | F | $0.15 |
| AMGNAmgen Inc | C | C | C | $371.58 |
| GILDGilead Sciences Inc | C | B | C | $136.30 |
| ARGXargenx SE American Depositary Shares | D | A | B | $857.97 |
| RVMDRevolution Medicines, Inc. Common Stock | F | — | A | $179.18 |
| BIIBBiogen Inc. Common Stock | B | D | B | $208.92 |
| BNTXBioNTech SE American Depositary Share | C | C | C | $91.56 |
| MRNAModerna, Inc. Common Stock | D | B | B | $63.15 |
| NBIXNeurocrine Biosciences Inc | C | B | B | $171.55 |
| EXELExelixis Inc | C | B | B | $55.68 |
| TECHBio-Techne Corp. | D | C | B | $71.77 |
About
Liminatus Pharma is a clinical-stage biopharmaceutical company developing the GCC Vaccine, an immunotherapy targeting cancers that express Guanylyl Cyclase C. The vaccine candidate is currently in Phase II clinical trials for colorectal, pancreatic, gastric, and esophageal cancers.